Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,457
datasets available to search
ShareScore release 0.9.0
Dataset results
1,457 results for “Patient factors”
A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]
ClinicalTrials.gov study NCT01003899. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
ClinicalTrials.gov study NCT03499353. IPD Sharing: YES. Countries: 1. Publications: 2.
A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency
ClinicalTrials.gov study NCT00883090. IPD Sharing: Not stated. Countries: 2. Publications: 1.
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Th
ClinicalTrials.gov study NCT01369329. IPD Sharing: Not stated. Countries: 23. Publications: 14.
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or
ClinicalTrials.gov study NCT00875979. IPD Sharing: Not stated. Countries: 7. Publications: 1.
Prophylaxis of Periprosthetic Joint Infections With Calcium Sulfate Beads in Patients With Non-modifiable Risk Factors.
ClinicalTrials.gov study NCT03976466. IPD Sharing: Not stated. Countries: 1. Publications: 64.
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
ClinicalTrials.gov study NCT04035486. IPD Sharing: YES. Countries: 21. Publications: 7.
Follow-on Protocol of Pitavastatin Versus Simvastatin in Patients With Hypercholesterolemia or Dyslipidemia and Coronary Heart Disease Risk Factors
ClinicalTrials.gov study NCT00344175. IPD Sharing: Not stated. Countries: 4. Publications: 1.
Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embo
ClinicalTrials.gov study NCT00439725. IPD Sharing: Not stated. Countries: 33. Publications: 6.
Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients
ClinicalTrials.gov study NCT01526928. IPD Sharing: Not stated. Countries: 4. Publications: 2.
Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT
ClinicalTrials.gov study NCT01232504. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Lo
ClinicalTrials.gov study NCT02091960. IPD Sharing: YES. Countries: 6. Publications: 1.
Risk Factors for Microvascular Obstruction Post-Emergency PCI in AMI Patients
ClinicalTrials.gov study NCT07042321. IPD Sharing: NO. Countries: 1. Publications: 3.
Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov study NCT00759798. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor
ClinicalTrials.gov study NCT01350804. IPD Sharing: Not stated. Countries: 15. Publications: 2.
Factors associated with coronary heart disease in COPD patients and controls
Open the record for dataset details and reuse information.
Assessment of cardiovascular risk factors in patients with Knee Osteoarthritis
Open the record for dataset details and reuse information.
Factors related to the implementation of patient safety culture in prehospital emergency services
Open the record for dataset details and reuse information.
Psychiatric manifestations and associated risk factors among hospitalized patients with COVID-19 in Edo State, Nigeria: A Cross-sectional Study
Open the record for dataset details and reuse information.
Aetiology and prognostic risk factors of mortality in pneumonia patients receiving glucocorticoids alone or glucocorticoids and other immunosuppressants: a retrospective cohort study
<p><b>Objectives:</b> Long-term use of high-dose glucocorticoids can lead to severe immunosuppression and increased risk of treatment-resistant pneumonia and mortality. We investigated the aetiology and prognostic risk factors of mortality in hospitalised patients who developed pneumonia while receiving glucocorticoid therapy alone or glucocorticoid and other immunosuppressant therapies.</p> <p><b>Design:</b> Retrospective cohort study</p> <p><b>Setting: </b>Six secondary and tertiary academic hospitals in China</p> <p><b>Participants: </b>Patients receiving glucocorticoids who were hospitalised with pneumonia between 1<sup>st</sup> January 2013 and 31<sup>st</sup> December 2019.</p> <p><b>Main Outcomes: </b>We analysed<b> </b>the prevalence of comorbidities, microbiology, antibiotic susceptibility patterns, 30-day and 90-day mortality rates, and prognostic risk factors.</p> <p><b>Results</b>: A total of 716 patients were included, with pneumonia pathogens identified in 69.8% of patients. Significant morbidities occurred, including respiratory failure (50.8%), intensive care unit (ICU) transfer (40.8%), and mechanical ventilation (36%), with a 90-day mortality rate of 26.0%. Diagnosis of pneumonia occurred within 6 months of glucocorticoid initiation for 69.7% of patients with <i>Cytomegalovirus</i> (CMV) pneumonia and 79.0% of patients with <i>Pneumocystis jirovecii</i> pneumonia (PCP). Pathogens, including <i>Pneumocystis</i>, CMV, and multidrug-resistant bacteria, were identified more frequently in patients with persistent lymphocytopenia and high-dose glucocorticoid treatment (≥ 30 mg/day of prednisolone or equivalent within 30 days before admission). The 90-day mortality rate was significantly lower for non-CMV viral pneumonias than for PCP (<i>P</i> < 0.05), with a similar mortality rate as CMV pneumonias (24.2% vs 38.1% vs 27.4%, respectively).Cox regression analysis indicated <a name="_Hlk30339725"></a><a name="_Hlk31278800">several independent negative predictors for mortality in this patient population, including septic shock, respiratory failure, </a>persistent lymphocytopenia, interstitial lung disease, and high-dose glucocorticoid use.</p> <p><b>Conclusions</b>: Patients who developed pneumonia while receiving glucocorticoid therapy experienced high rates of opportunistic infections, with significant morbidity and mortality. These findings should be carefully considered when determining treatment strategies for this patient population.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.